Literature DB >> 19075281

American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment.

Robin T Zon1, Elizabeth Goss, Victor G Vogel, Rowan T Chlebowski, Ismail Jatoi, Mark E Robson, Dana S Wollins, Judy E Garber, Powel Brown, Barnett S Kramer.   

Abstract

Oncologists have a critical opportunity to utilize risk assessment and cancer prevention strategies to interrupt the initiation or progression of cancer in cancer survivors and individuals at high risk of developing cancer. Expanding knowledge about the natural history and prognosis of cancers positions oncologists to advise patients regarding the risk of second malignancies and treatment-related cancers. In addition, as recognized experts in the full spectrum of cancer care, oncologists are afforded opportunities for involvement in community-based cancer prevention activities. Although oncologists are currently providing many cancer prevention and risk assessment services to their patients, economic barriers exist, including inadequate or lack of insurance, that may compromise uniform patient access to these services. Additionally, insufficient reimbursement for existing and developing interventions may discourage patient access to these services. The American Society of Clinical Oncology (ASCO), the medical society representing cancer specialists involved in patient care and clinical research, is committed to supporting oncologists in their wide-ranging involvement in cancer prevention. This statement on risk assessment and prevention counseling, although not intended to be a comprehensive overview of cancer prevention describes the current role of oncologists in risk assessment and prevention; provides examples of risk assessment and prevention activities that should be offered by oncologists; identifies potential opportunities for coordination between oncologists and primary care physicians in prevention education and coordination of care for cancer survivors; describes ASCO's involvement in education and training of oncologists regarding prevention; and proposes improvement in the payment environment to encourage patient access to these services.

Entities:  

Mesh:

Year:  2008        PMID: 19075281      PMCID: PMC2668639          DOI: 10.1200/JCO.2008.16.3691

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  59 in total

1.  Prevention of hepatocellular carcinoma.

Authors:  Jack R Wands
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

2.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Authors:  Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Scott M Lippman; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark
Journal:  JAMA       Date:  2006-06-05       Impact factor: 56.272

Review 3.  Review of exercise intervention studies in cancer patients.

Authors:  Daniel A Galvão; Robert U Newton
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

4.  Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996.

Authors: 
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

5.  Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  H Meijers-Heijboer; B van Geel; W L van Putten; S C Henzen-Logmans; C Seynaeve; M B Menke-Pluymers; C C Bartels; L C Verhoog; A M van den Ouweland; M F Niermeijer; C T Brekelmans; J G Klijn
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

Review 6.  Physical exercise in cancer patients during and after medical treatment: a systematic review of randomized and controlled clinical trials.

Authors:  Ruud Knols; Neil K Aaronson; Daniel Uebelhart; Jaap Fransen; Geert Aufdemkampe
Journal:  J Clin Oncol       Date:  2005-06-01       Impact factor: 44.544

7.  Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck.

Authors:  W K Hong; S M Lippman; L M Itri; D D Karp; J S Lee; R M Byers; S P Schantz; A M Kramer; R Lotan; L J Peters
Journal:  N Engl J Med       Date:  1990-09-20       Impact factor: 91.245

Review 8.  Promoting health and physical function among cancer survivors: potential for prevention and questions that remain.

Authors:  Wendy Demark-Wahnefried; Bernardine M Pinto; Ellen R Gritz
Journal:  J Clin Oncol       Date:  2006-11-10       Impact factor: 44.544

9.  Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.

Authors:  L C Hartmann; D J Schaid; J E Woods; T P Crotty; J L Myers; P G Arnold; P M Petty; T A Sellers; J L Johnson; S K McDonnell; M H Frost; R B Jenkins
Journal:  N Engl J Med       Date:  1999-01-14       Impact factor: 91.245

10.  Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer.

Authors:  G P Browman; G Wong; I Hodson; J Sathya; R Russell; L McAlpine; P Skingley; M N Levine
Journal:  N Engl J Med       Date:  1993-01-21       Impact factor: 91.245

View more
  26 in total

1.  Can physicians refuse treatment to patients who smoke?

Authors:  Timothy M Pawlik; Ian N Olver; Courtney D Storm; Maria Alma Rodriguez
Journal:  J Oncol Pract       Date:  2009-09       Impact factor: 3.840

2.  Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic.

Authors:  Frank L Meyskens; Gregory A Curt; Dean E Brenner; Gary Gordon; Ronald B Herberman; Olivera Finn; Gary J Kelloff; Samir N Khleif; Caroline C Sigman; Eva Szabo
Journal:  Cancer Prev Res (Phila)       Date:  2011-03

3.  Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.

Authors:  Channing J Paller; Emmanuel S Antonarakis; Tomasz M Beer; Hala T Borno; Maria I Carlo; Daniel J George; Julie N Graff; Shilpa Gupta; Elisabeth I Heath; Celestia S Higano; Rana R McKay; Alicia K Morgans; Akash Patnaik; Daniel P Petrylak; Matthew B Rettig; Charles J Ryan; Mary-Ellen Taplin; Young E Whang; Jacob Vinson; Heather H Cheng; Veda N Giri
Journal:  Clin Genitourin Cancer       Date:  2019-04-18       Impact factor: 2.872

4.  Associations between e-cigarette and combustible cigarette use among U.S. cancer survivors: implications for research and practice.

Authors:  Godfred O Antwi; David K Lohrmann; Wasantha Jayawardene; Angela Chow; Cecilia S Obeng; Aaron M Sayegh
Journal:  J Cancer Surviv       Date:  2019-04-06       Impact factor: 4.442

5.  American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care.

Authors:  Mary S McCabe; Smita Bhatia; Kevin C Oeffinger; Gregory H Reaman; Courtney Tyne; Dana S Wollins; Melissa M Hudson
Journal:  J Clin Oncol       Date:  2013-01-07       Impact factor: 44.544

6.  American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers.

Authors:  Karen H Lu; Marie E Wood; Molly Daniels; Cathy Burke; James Ford; Noah D Kauff; Wendy Kohlmann; Noralane M Lindor; Therese M Mulvey; Linda Robinson; Wendy S Rubinstein; Elena M Stoffel; Carrie Snyder; Sapna Syngal; Janette K Merrill; Dana Swartzberg Wollins; Kevin S Hughes
Journal:  J Clin Oncol       Date:  2014-02-03       Impact factor: 44.544

7.  Educational Needs of Oncology Practitioners in a Regional Cancer Center in the Middle East-Improving the Content of Smoking Cessation Training Programs.

Authors:  N A Obeidat; F I Hawari; R Amarin; B Aburajab Altamimi; I M Ghonimat
Journal:  J Cancer Educ       Date:  2017-12       Impact factor: 2.037

Review 8.  Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.

Authors:  Tuya Pal; Susan T Vadaparampil
Journal:  Cancer Control       Date:  2012-10       Impact factor: 3.302

9.  Physical activity preferences of early-stage lung cancer survivors.

Authors:  Errol J Philip; Elliot J Coups; Marc B Feinstein; Bernard J Park; Donna J Wilson; Jamie S Ostroff
Journal:  Support Care Cancer       Date:  2013-10-05       Impact factor: 3.603

Review 10.  Decision making about cancer screening: an assessment of the state of the science and a suggested research agenda from the ASPO Behavioral Oncology and Cancer Communication Special Interest Group.

Authors:  Marc T Kiviniemi; Jennifer L Hay; Aimee S James; Isaac M Lipkus; Helen I Meissner; Michael Stefanek; Jamie L Studts; John F P Bridges; David R Close; Deborah O Erwin; Resa M Jones; Karen Kaiser; Kathryn M Kash; Kimberly M Kelly; Simon J Craddock Lee; Jason Q Purnell; Laura A Siminoff; Susan T Vadaparampil; Catharine Wang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-11       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.